99mTc-biciromab

N/A

Report date: 2025/09/08 14:40:43

Base Information

Drug Name99mTc-biciromab

Drug Alias Nametechnetium-99m biciromabtechnetium-99m Fibriscint99mTc-Fibriscint99m-Tc-AF

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionFibrinogen beta chain inhibitors

TargetsFibrinogen beta chain

Therapy Area/IndicationsThromboembolism

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJohnson & Johnson Innovative Medicine

Active IndicationsN/A

Inactive IndicationsThromboembolism

Other Information

ATC CodeN/A